※ 출처: ClinicalTrials.gov
총 786건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, Chronic, B-Cell Drug: JNJ-64264681 Janssen Research & Development, LLC Phase 1 2020-07-01
2 An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA Biological: Nivolumab|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Docetaxel|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Other: Observation Bristol-Myers Squibb Phase 2 2020-06-15
3 Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Cough Drug: Gefapixant|Drug: Placebo Merck Sharp & Dohme Corp. Phase 3 2020-05-10
4 Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue of Subjects With Rheumatoid Arthritis (RA) Rheumatoid Arthritis Drug: Tc 99m tilmanocept Navidea Biopharmaceuticals Phase 2 2020-05-01
5 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Compensated Cirrhosis|Nonalcoholic Steatohepatitis Biological: aldafermin|Other: Placebo NGM Biopharmaceuticals, Inc Phase 2 2020-03-23
6 A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. Bladder Cancer|Bladder Tumor|Muscle-Invasive Bladder Cancer Biological: Nivolumab|Biological: NKTR-214|Procedure: Radical cystectomy (RC) Bristol-Myers Squibb|Nektar Therapeutics Phase 3 2020-01-23
7 Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer Colorectal Neoplasms Biological: TG6002|Drug: Flucytosine (5-FC) Transgene Phase 1|Phase 2 2020-01-17
8 Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type IIIA Mucopolysaccharidosis Type IIIA Drug: Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene University of Manchester|Orchard Therapeutics|CTI Clinical Trial and Consulting Services|University College, London|Great Ormond Street Hospital for Children NHS Foundation Trust|Manchester University NHS Foundation Trust Phase 1|Phase 2 2020-01-07
9 Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) Diffuse Cutaneous Systemic Sclerosis Biological: IgPro10|Biological: Placebo CSL Behring Phase 2 2019-12-20
10 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Triple Negative Breast Neoplasms Biological: Pembrolizumab|Drug: Olaparib|Drug: Carboplatin|Drug: Gemcitabine Merck Sharp & Dohme Corp. Phase 2|Phase 3 2019-12-19